Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
September 07, 2021 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug...